Breast cancer survival in the US and Europe: a CONCORD high-resolution study. by Allemani, Claudia et al.
Allemani, C; Sant, M; Weir, HK; Richardson, LC; Baili, P; Storm,
H; Siesling, S; Torrella-Ramos, A; Voogd, AC; Aareleid, T; Ardanaz,
E; Berrino, F; Bielska-Lasota, M; Bolick, S; Cirilli, C; Colonna, M;
Contiero, P; Cress, R; Crocetti, E; Fulton, JP; Grosclaude, P; Haku-
linen, T; Izarzugaza, MI; Malmstrm, P; Peignaux, K; Primic-akelj,
M; Rachtan, J; Safaei Diba, C; Snchez, MJ; Schymura, MJ; Shen, T;
Traina, A; Tryggvadottir, L; Tumino, R; Velten, M; Vercelli, M; Wolf,
HJ; Woronoff, AS; Wu, X; Coleman, MP (2013) Breast cancer sur-
vival in the US and Europe: A CONCORD high-resolution study. In-
ternational journal of cancer Journal international du cancer, 132 (5).
pp. 1170-81. ISSN 0020-7136 DOI: https://doi.org/10.1002/ijc.27725
Downloaded from: http://researchonline.lshtm.ac.uk/103753/
DOI: 10.1002/ijc.27725
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
Breast cancer survival in the US and Europe: a CONCORD high-
resolution study
Claudia Allemani, PhD1,2, Milena Sant, MD2, Hannah K Weir, PhD3, Lisa C Richardson, 
MD3, Paolo Baili, PhD4, Hans Storm, MD5, Sabine Siesling, PhD6, Ana Torrella-Ramos, 
MD7, Adri C Voogd, PhD8, Tiiu Aareleid, MD9, Eva Ardanaz, PhD10, Franco Berrino, MD11, 
Magdalena Bielska-Lasota, MD12, Susan Bolick, MSPH13, Claudia Cirilli, BSc14, Marc 
Colonna, PhD15, Paolo Contiero, PhD16, Rosemary Cress, DrPH17, Emanuele Crocetti, 
MD18, John P Fulton, PhD19, Pascale Grosclaude, MD20, Prof Timo Hakulinen21, M Isabel 
Izarzugaza, MD22, Prof Per Malmström23, Karin Peignaux, PhD24, Maja Primic-Žakelj, MD25, 
Prof Jadwiga Rachtan26, Chakameh Safaei Diba, MD27, Maria-José Sánchez, MD28, Maria J 
Schymura, PhD29, Tiefu Shen, MD30, Adele Traina, MD31, Prof Laufey Tryggvadottir32,33, 
Rosario Tumino, MD34, Michel Velten, MD35, Marina Vercelli, PhD36,37, Holly J Wolf, PhD38, 
Anne-Sophie Woronoff, MD39, Xiaocheng Wu, MD40, and Prof Michel P Coleman1
1Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease 
Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 
7HT, UK 2Analytical Epidemiology Unit, Department of Preventive and Predictive Medicine, 
Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, I-20133 Milan, Italy 3Division of 
Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford 
Highway NE, MS-K53 Atlanta, GA 30341-3742, USA 4Descriptive Studies and Health Planning 
Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, I-20133 Milan, Italy 
5Department of Cancer Prevention and Documentation, Danish Cancer Society, 
Strandboulevarden 49, Copenhagen Ø, Denmark 6Netherlands Cancer Registry, Comprehensive 
Cancer Centre the Netherlands, PO Box 19079, 3501 DB Utrecht, The Netherlands 7Cancer 
Registry Castellón (Comunitat Valenciana), Avenida del Mar 12, E-12003 Castellón, Spain 
8Department of Research, Eindhoven Cancer Registry, PO Box 231, 5600 AE Eindhoven, The 
Netherlands 9Department of Epidemiology and Biostatistics, National Institute for Health 
Development, Hiiu St 42, 11619 Tallinn, Estonia 10Navarra Cancer Registry, Navarra Public 
Health Institute (CIBERESP), C Leyre 15, 31003 Pamplona, Navarra, Spain 11Unit of Etiological 
Epidemiology and Prevention, Department of Preventive and Predictive Medicine, Fondazione 
IRCCS Istituto Nazionale dei Tumori, Milan Italy 12Bioethics and Health Psychology Unit, 
Department of Health Promotion and Postgraduate Education, National Institute of Public Health, 
National Institute of Hygiene, 24 Chocimska str, 00-791 Warsaw, Poland 13South Carolina Central 
Corresponding author: Claudia Allemani PhD, Lecturer in Cancer Epidemiology, Cancer Research UK Cancer Survival Group, 
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London 
WC1E 7HT, UK, claudia.allemani@lshtm.ac.uk Tel: +44 (0)20 7927 2855. 
Novelty and impact of the work: Most of the diagnostic and therapeutic modalities used for breast cancer more than 10 years ago 
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standard quality-control procedures and central analyses. The modelling approach to estimate net survival is a methodological 
strength.
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Abstract
Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study 
(CONCORD) found wide international differences in age-standardised survival. The aim of this 
study is to explain these survival differences.
Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were 
collected for about 20,000 women diagnosed with breast cancer aged 15–99 years during 1996–98 
in 7 US states and 12 European countries. Age-standardised net survival and the excess hazard of 
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death up to five years after diagnosis were estimated by jurisdiction (registry, country, European 
region), age and stage with flexible parametric models.
Breast cancers were generally less advanced in the US than in Europe. Stage also varied less 
between US states than between European jurisdictions. Early, node-negative tumours were more 
frequent in the US (39%) than in Europe (32%), while locally advanced tumours were twice as 
frequent in Europe (8%), and metastatic tumours of similar frequency (5–6%). Net survival in 
Northern, Western and Southern Europe (82–85%) was similar to that in the US (84%), but lower 
in Eastern Europe (72%). For the first 3 years after diagnosis the mean excess hazard was higher 
in Eastern Europe than elsewhere: the difference was most marked for women aged 70–99 years, 
and mainly confined to women with locally advanced or metastatic tumours.
Differences in breast cancer survival between Europe and the US in the late 1990s were mainly 
explained by lower survival in Eastern Europe, where low healthcare expenditure may have 
constrained the quality of treatment.
Keywords
CONCORD; net survival; excess hazard; cancer registries
Introduction
Breast cancer survival has been reported as higher in the US than in Europe1,2. For women 
diagnosed 1985–89, five-year survival was higher in each of the nine Surveillance, 
Epidemiology and End Results (SEER) areas than in any of the 22 European countries 
participating in the EUROCARE-2 study.
The first worldwide analysis of cancer survival (CONCORD3) provided a systematic 
comparison of survival for adults (15–99 years) diagnosed with a cancer of the breast, colon, 
rectum or prostate in one of 31 countries during 1990–94 and followed up to 1999. 
International differences in age-standardised survival were very wide, even after adjustment 
for differences in mortality from other causes of death. Breast cancer survival in the US and 
Canada was higher than in other countries, but differences between the US and most 
European regions were smaller than for women diagnosed during 1985–892. The largest 
differences were between the US and Eastern Europe.
A population-based comparison of five-year breast cancer survival among women diagnosed 
in 17 territories in 6 European countries during 1990–92 and in the 9 states and metropolitan 
areas of the US covered by the SEER programme in 1990 showed that differences were 
mainly attributable to stage at diagnosis and the diagnostic procedures used to determine the 
stage4.
Both the assiduity of investigation and the appropriateness of treatment by stage varied 
widely for women diagnosed in Europe during 1990–92 and 1996–985,6. Primary treatment 
for breast cancer also varies greatly throughout the US7,8. Following the NIH Consensus 
Development Conference in 1990, which recommended breast-conserving surgery and 
radiotherapy instead of mastectomy for women with stage I and II breast cancer, the 
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proportion treated with breast-conserving surgery increased steadily up to 19959, but the 
percentage who also received radiotherapy and/or axillary lymphadenectomy declined10. 
Differences in protocol and calendar period make it difficult to draw firm conclusions from 
these studies about whether the differences in survival between Europe and the US are 
attributable to differences in stage, or treatment, or both.
The CONCORD protocol incorporated “high-resolution” studies designed to explain the 
international variations in survival for breast, colorectal and prostate cancer. The analyses 
involve large random samples of patients, with detailed clinical and pathological data that 
are not routinely abstracted by population-based cancer registries. The study reported here 
provides a trans-Atlantic comparison of stage, treatment and survival for women with breast 
cancer. The aims were to compare the stage distributions in Europe and the US; to determine 
whether the transatlantic differences in 5-year survival persist and, if so, to assess the extent 
to which they are attributable to differences in stage. We also set out to compare adherence 
to “standard care” for breast cancer in relation to age, stage and hormone receptor status, 
before widespread introduction of clinical guidelines.
Material and methods
Data on stage, diagnostic procedures, treatment and follow-up were collected for a 
representative sample of about 20,000 women aged 15–99 years who were registered with a 
diagnosis of breast cancer in the US or one of 12 European countries during 1996–98. A 
common protocol was used, based on the EUROCARE high-resolution protocols5,6.
The European data were provided by 26 population-based cancer registries in 12 countries, 7 
of which with national coverage, denoted by an asterisk (*). For some analyses, the data 
were grouped into four European regions defined by the United Nations (UN, http://
unstats.un.org/unsd/methods/m49/m49regin.htm) - Northern Europe: Denmark*, Finland*, 
Iceland*, Sweden*; Western Europe: France (Bas-Rhin, Côte d’Or, Doubs, Isère, Tarn) and 
the Netherlands (Eindhoven, North East Netherlands); Southern Europe: Italy (Firenze, 
Genova, Modena, Palermo, Ragusa, Varese), Slovenia*, Spain (Basque Country, Castellon, 
Granada, Navarra); Eastern Europe: Estonia*, Poland (Cracow, Warsaw), Slovakia*. 
Estonia is classified by the UN as being in Northern Europe, but cancer survival has usually 
resembled that in Eastern European countries11, and the data from Estonia are included here 
with Eastern Europe. Data from the US were provided by 7 state-wide registries: California, 
Colorado, Illinois, Louisiana, New York, Rhode Island and South Carolina. The US 
registries are part of the National Program of Cancer Registries, based at the Centers for 
Disease Control and Prevention.
For this study the cancer registries included in the EUROCARE-3 high-resolution study6 
made special efforts to update the follow-up to at least five years after diagnosis for all 
patients. The North East Netherlands registry was not included in EUROCARE-3, but it is 
unusual in that it routinely collects almost all the data required for high-resolution studies on 
all registered cancer patients, so it was able to provide such data on virtually all women with 
breast cancer, not just a sample.
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Most European registries provided a random sample of at least 500 women diagnosed during 
1996–98, as specified by the protocol. Denmark and Sweden provided a sample of women 
diagnosed in 1994, and Palermo (Italy) provided data for all women diagnosed in 1999, the 
first year for which data were available there. The Finnish cases were a population-based 
sample of women diagnosed in the Tampere hospital region, which is considered 
representative of the whole of Finland. Despite these slight departures from protocol, these 
cases were retained to ensure the widest possible geographic coverage. Each of the US 
registries provided a random sample of at least 500 women diagnosed with breast cancer in 
1997.
Anonymised, individual cancer registration records were supplied for 20,150 women 
diagnosed with a malignant neoplasm of the breast. In situ tumours (1,168, 5.8%) were 
excluded from the analyses because they were collected systematically in the US, but not in 
Europe. A further 20 cases (0.1%) were excluded because they did not meet the protocol (2 
with benign or uncertain behaviour, 2 with the morphology of leukaemia or lymphoma, and 
16 aged less than 15 or more than 100 years). In all, 18,962 women with a primary, invasive, 
malignant neoplasm of the breast were included in the analysis of stage and treatment. 
Women whose cancer was only registered from a death certificate (23; 0.1%), or of 
unknown vital status (18; 0.1%), or for whom the date of last known vital status preceded 
the date of diagnosis (32; 0.2%), were excluded from the survival analyses, which thus 
involved 18,889 women.
Information on stage, diagnostic examinations, treatment and follow-up was obtained by 
direct examination of the clinical record. Where records were incomplete, pathology reports, 
hospital discharge records and other sources were consulted as necessary.
Disease stage was defined according to the 4th edition of the TNM (Tumour, Nodes, 
Metastasis) manual.12 If pathological data on tumour size and lymph node status (pT and 
pN) were unavailable, clinical data (cT and cN) were used. Following advice from 
epidemiologists, pathologists and clinicians, records for which the metastatic status was 
unknown (MX) were considered as negative (M0), if T and N were known. Patients were 
grouped into six categories: early, node-negative disease (T1N0M0), larger node-negative 
(T2-3N0M0), node-positive (T1-3N+M0), locally advanced (T4, any N, M0), metastatic 
(M1) and unstaged. Within the category of early, node-negative disease, we also assessed 
the distribution of small tumours by size: less than 5mm (T1a), 5–10mm (T1b) and over 
10mm and up to 20mm (T1c). Estrogen-receptor (ER) status was categorized as positive, 
negative or unknown. Age at diagnosis was categorised into four groups (15–39, 40–49, 50–
69, 70–99 years) for survival analysis. Treatment comparisons were made in wider age 
groups: 15–49 and 50–99 years for chemotherapy and hormone therapy; 15–69 and 70–99 
years for breast-conserving surgery plus radiotherapy.
Data on surgical procedures were collected in 7 categories: conservative surgery (including 
quadrantectomy, tumour excision, lumpectomy), simple mastectomy, any modified radical 
mastectomy, extended radical (Halsted) mastectomy, surgery (not otherwise specified), 
unknown if surgery was performed, and no surgery. When a surgical procedure was 
performed, axillary procedures were collected in 5 categories: for lymph-node sampling, for 
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axillary clearance, unspecified whether for sampling or clearance, not specified if done or 
not, and not done. Information was also sought on sentinel lymph-node biopsy, with or 
without lymphadenectomy, but sentinel biopsy was very uncommon during 1996–98. 
Information on biopsy or needle aspiration of the breast was coded in 5 categories as either 
done; not done because of refusal or death, or for specified medical contraindications, or for 
other or unspecified reasons; or unknown if done or not. Chemotherapy, radiotherapy and 
hormonal therapy were coded as yes, no or unknown.
Primary treatment for early node-negative disease was dichotomised as breast-conserving 
surgery with radiotherapy (BCS+RT) vs. all other surgical procedures, whether or not 
followed by radiotherapy. Chemotherapy and endocrine treatment were dichotomised as 
administered vs. not administered or unknown.
Statistical Analysis
We examined the proportion of women with early, node-negative disease who received 
breast-conserving surgery plus radiotherapy; the proportion of women with node-positive 
disease who received chemotherapy; the proportion of women with estrogen-receptor-
positive tumours who received tamoxifen, and the proportion of women for whom at least 
10 lymph nodes were removed and examined during lymphadenectomy, as recommended in 
the TNM manual for staging breast cancer from 1992 (4th edition, 2nd revision)12. Cancer 
registry data sets were excluded if data on stage and/or treatment were missing for 20% or 
more of patients. Thus Firenze and Ragusa were excluded from the analyses of 
chemotherapy in node-positive disease, and Firenze, Genova and Ragusa were excluded 
from the analyses of hormonal treatment in estrogen-receptor-positive disease.
Net survival up to five years after diagnosis was estimated by jurisdiction (registry, country 
and European region), age and stage using flexible parametric excess hazard models13. Net 
survival is the survival of cancer patients in the hypothetical situation when the cancer may 
be assumed to be the only possible cause of death; it may be interpreted as cancer survival 
after controlling for competing causes of death. Net survival was estimated with a modelling 
approach14,15, in which the total hazard of death is considered as the sum of the cancer-
related mortality hazard (excess hazard), and the hazard of death from other causes 
(background hazard). The background hazard is derived from life tables of all-cause 
mortality by sex, single year of age and calendar year in the general population of the 
country, region or (in the US) state from which the cancer patients are drawn. We 
constructed period life tables for 1994–2004 with the approaches proposed by Baili et al.16.
Age was included as a continuous variable in all models, in order to avoid the bias in the 
estimation of net survival that would otherwise arise from differential loss of the oldest 
patients (informative censoring). Both non-linear and time-dependent (interaction with time 
since diagnosis) effects of age were initially modelled with cubic splines. The 
proportionality of the effect of tumour stage on the excess hazard was also assessed. Simpler 
models, with linear and/or proportional effects, were successively tested and selected using 
the Akaike Information Criterion for goodness of fit17. We also estimated the instantaneous 
excess risk (hazard) of death due to breast cancer, after subtracting the hazard from all other 
causes of death14,15,18,19. We present the mean excess hazard per 1,000 person-years at risk 
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at 1 month, 6 months and 1, 3 and 5 years since diagnosis, both by age and by stage at 
diagnosis after adjustment for age.
Overall (all-ages) net survival estimates were age-standardised with the international cancer 
survival standard (ICSS) weights20.
We used a logistic regression model to estimate the odds of women with early node-negative 
disease receiving breast-conserving surgery and radiotherapy (vs. any other surgical 
procedure, with or without radiotherapy) in each jurisdiction, after adjustment for age and 
tumour size.
Survival analyses were performed with stpm218 in Stata version 11 (StataCorp LP, College 
Station, TX).
Results
We included 18,962 women with invasive primary breast cancer: 15,842 women in 26 
jurisdictions in 12 European countries and 3,120 women in 7 US states (Table 1). 
Microscopic verification was available for 98–99% of the women in each of the US states 
and 94% in Europe, ranging from 79% in Estonia to 100% in the Basque country (Spain). 
Data were available on stage for about 90% of cases in both data sets, ranging from 78% 
(Ragusa, Italy) to 95% or more in 8 of the 26 European registries and from 81% (New York) 
to 94% (Colorado and S Carolina) in the US.
Breast cancers were generally less advanced in the US than in Europe, and the stage 
distribution varied less between US states than between European jurisdictions. Early node-
negative tumours were more frequent in the US (39%, range 33–45%) than in Europe (32%, 
16–49%). Large node-negative tumours were of similar frequency (Europe 14%, 9–22%; US 
14%, 10–18%), while node-positive tumours were more common in Europe (33%, 25–44%) 
than the US (26%, 22–29%). Locally advanced tumours were twice as frequent in Europe 
(8%, 0–24%) as in the US (4%, 3–6%), but the overall frequency of metastatic tumours was 
similar (5–6%). The proportion of tumours with unspecified stage was slightly higher in the 
US (11%) than Europe (8%), but up to 18–22% in three European registries (Finland; Italy: 
Firenze, Ragusa), while only New York (19%) differed much from the US average. 
Exclusion of these registries did not substantially alter the overall stage distributions in 
Europe or the US (data not shown).
Lymphadenectomy was reported for 13,687 (86%) women in Europe and 2,531 (81%) in the 
US, but it was generally more extensive in the US, where 10 or more nodes were examined 
in 78% (range 76–83%) of procedures, compared with 66% (23–93%) in Europe (Table 2). 
Among women with early node-negative tumours, the distribution of tumour size was more 
favourable in the US than in Europe.
More than 90% of women received surgical treatment: 91% in Europe (from 77% in Estonia 
to 95% or more in 10 of 26 jurisdictions) and 96% in the US (93–97%; Table 3). Among 
operated women, 35% had early node-negative disease in Europe, compared with 41% in the 
US. Among women operated for early node-negative disease, breast-conserving surgery plus 
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radiotherapy was received by 55% in Europe and 49% in the US, but the variability was 
much wider in Europe (9% in Estonia; 78–84% in four of the five French regions) than in 
the US (34% in S Carolina; 58% in Rhode Island). The proportion of women aged 70–99 
years who received breast-conserving surgery and radiotherapy for early node-negative 
disease varied more between European countries and regions (4–6% in two Polish regions; 
84% in Tarn) than between US states (21% in Louisiana; 47–48% in Rhode Island and 
California).
For early node-negative disease, and relative to Southern Europe (1,848 women, reference 
category), the odds of receiving both breast-conserving surgery and radiotherapy (vs. any 
other surgical procedure, with or without radiotherapy), adjusted for age and tumour size, 
were lower in the US (OR=0.80; 95%CI 0.69–0.94) and Northern Europe (OR=0.60; 0.50–
0.72); much lower in Eastern Europe (OR=0.16; 0.12–0.20), and higher in Western Europe 
(OR=1.57; 1.36–1.81) (Table 4). The odds of receiving this treatment were significantly 
lower for women aged 70–99 years than for those aged 60–69 years (OR=0.48; 0.41–0.56), 
after adjustment for region and tumour size. Women with tumours of 5–10mm (T1b) 
received this treatment more than women with larger tumours (up to 20mm, T1c) (OR=1.31; 
1.16–1.48).
Among women with node-positive tumours, 58% received chemotherapy in the 26 European 
jurisdictions, compared with 69% in the 7 US states (Table 5). Among women aged less 
than 50 at diagnosis, the overall proportion was similar in Europe and the US (90%), but the 
range was wider in Europe (54–100%) than the US (84–94%). Among older women, the 
proportion who received chemotherapy was higher, and varied less, in the US (60%, range 
53–67%) than in Europe (46%, range 14–75%).
Overall, endocrine treatment in ER-positive tumours was slightly higher in the US (62%) 
than in Europe (55%). The proportion was similar in women aged 50 and over (63% in the 
US; 59% in Europe), but younger women received tamoxifen more often in the US (58% vs. 
44%).
Overall, age-standardised net survival at five years was 81% in Europe and 84% in the US 
(Figure 1). Survival in Northern, Western and Southern Europe (81–84%) was similar to that 
in the US (84%), but it was lower in Eastern Europe (69%). Survival varied more widely 
between European jurisdictions (88% in Iceland to 62% in Estonia) than between US states 
(from 91% in Colorado to 76% in South Carolina).
Five-year age-standardised net survival was broadly similar in all European regions and the 
US for early, node-negative tumours (96–98%) and for large, node-negative tumours (85–
90%) (Figure 2, available in web-appendix). The geographic range in survival was much 
wider for locally advanced disease, from 37% in Eastern Europe to 77% in Northern Europe, 
and 44% in the US. As with overall survival, stage-specific five-year survival was similar in 
Northern, Western and Southern Europe and the US. In Eastern Europe, survival for node-
positive, locally advanced and metastatic tumours was lower than in other European regions 
or the US.
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The mean excess hazard was higher in Eastern Europe than in other jurisdictions at 1 month, 
6 months and 1, 3 and 5 years after diagnosis, both for all ages and in each of 5 age 
categories (Figure 3, available in web-appendix). The difference was most marked for 
women aged 70–99 years. No striking differences were found between Northern, Western, 
Southern Europe and the US. The high excess hazard of death in Eastern Europe was mainly 
confined to women with locally advanced or metastatic tumours (Figure 4, available in web-
appendix).
Discussion
Transatlantic differences in cancer survival have raised questions about early diagnosis and 
the adequacy of investigation and treatment. To our knowledge, this is the first population-
based high-resolution study to use clinical data that were collected by trained abstractors 
from the primary medical records under a common protocol, subjected to standard quality 
control procedures and analysed centrally with the same statistical methods. We compared 
survival using clinical data on stage, diagnostic procedures and treatment. The survival 
differences appear likely to be related to differences in diagnosis and patterns of care shortly 
after diagnosis. The women were diagnosed more than 10 years ago, but most diagnostic 
and therapeutic approaches used at that time remain in widespread use: understanding their 
role in international differences in survival remains relevant.
Overall, five-year net survival was not very different in Europe (81%) and the US (84%). 
Differences were mainly confined to the three Eastern European countries, Estonia, Poland 
and Slovakia, where average five-year survival was 69%. Estonia and Slovakia are both 
covered by national cancer registries, and the women from those countries were thus 
nationally representative. Survival varied more widely between the 26 European 
jurisdictions than between the 7 US states.
The differences in survival between Europe and the US in the late 1990s are smaller than for 
women diagnosed at the beginning of the decade3,4. In the previous high-resolution study4, 
the US data were taken from the SEER public-use data set21 and harmonised to the extent 
possible with the data collected under the EUROCARE-2 high-resolution protocol. By 
contrast, the data for this study were collected directly from the clinical records using a 
standard protocol; European coverage rose from 17 to 26 registries (11 contributed to both 
studies), and US coverage changed from the 5 metropolitan areas and 4 states covered by the 
SEER program to 7 state-wide registries in the National Program of Cancer Registries 
(NPCR). Survival in the 1990s was lower in the NPCR territories than the SEER areas3,22. 
Finally, in the previous high-resolution study, differences in background mortality in the US 
were controlled with a single national life table for 1990, weighted for the proportion of 
Blacks, Whites and other races, whereas we were able to use state-specific life tables for 
each calendar year 1994–2004.
The modelling approach used to estimate net survival is a strength of this study, but it does 
not explain the smaller transatlantic differences than those obtained with relative survival in 
the previous study. We found similar patterns with all the other widely used methods for 
survival estimation (data not shown).
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The European differences in survival were generally similar to those reported for the same 
countries among women diagnosed 1995–9911. Survival was higher than expected in 
Denmark (84%): the data in this study are from eastern Denmark, greater Copenhagen and 
Copenhagen (Zeeland), where most of the population has undergone mammographic 
screening since 199123. In these areas, survival after mammographic diagnosis is higher than 
in Denmark as a whole, regardless of whether it was a screening mammography. Survival in 
Slovenia was lower than in other Southern European countries, and more similar to that in 
Eastern Europe. Variation in survival between the 7 US states was less marked than in 
Europe, mostly in the range 81–87%, but ranging from 91% in Colorado to 76% in South 
Carolina, where Blacks represent approximately 30% of the population (http://
www.ipspr.sc.edu/publication/Older%20SC.pdf).
The availability of information about race in this data set would have strengthened the 
international survival comparisons, but information about race is not available in many 
European countries. Race in the US and geographical area in Europe are often considered as 
a proxy for socio-economic status. In future studies, it would be preferable to use life tables 
that are specific for race and/or socio-economic status.
Stage-specific net survival was similar in most European jurisdictions and US states. In 
Eastern Europe, survival from node-positive, large and metastatic tumours (N+; T4; M1) 
was lower than in other European regions or the US, and the proportion of metastatic 
tumours was also high, mainly in Estonia and Slovakia.
The mean excess hazard of death by time since diagnosis was similar in Europe and the US 
for women with early node-negative disease, large node-negative disease or node-positive 
disease, and up to five years after diagnosis. The hazard was somewhat higher in Eastern 
Europe for locally advanced disease, and much higher for metastatic disease, especially in 
the first three years after diagnosis. Adjustment for the number of examined lymph nodes, 
necessarily restricted to women who underwent lymphadenectomy (86%), did not modify 
this pattern, either overall, or within each category of stage. In other words, the geographic 
pattern in the mean excess hazard of death was not affected by the number of nodes 
examined during lymphadenectomy (data not shown). This suggests that, in contrast with 
the findings from the study of women diagnosed in 19904, stage migration does not affect 
the comparison of stage-specific survival between European regions and the US. This could 
be because the recording of stage has become more homogeneous, or because the quality 
and completeness of diagnostic investigation is less variable now than previously.
The mean excess hazard of death for women with late-stage disease was very high in 
Eastern Europe. This suggests that fewer effective treatment options were available for these 
women, although higher levels of co-morbidity may have restricted therapeutic options. 
Hormonal treatment and adjuvant chemotherapy were used more extensively in Slovakia, 
Estonia and Poland than in other European countries, and not just for node-positive and 
estrogen-receptor positive disease. Mastectomy was often used instead of breast-conserving 
surgery and radiotherapy, in part because radiotherapy facilities were not always available. 
Total national expenditure on health was low, and this is also likely to have affected the 
quality of treatment6.
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Data on stage were remarkably complete, because they were collected directly from clinical 
records. Complete data on stage and lymph nodes were unavailable for all but 5–11% of 
women in the 5 broad European regions, although for up to 20% in 3 of the 26 European 
registries. However, exclusion of women with unknown stage or lymph node status did not 
change the geographic pattern of the excess hazard of death within any of the categories for 
which stage was known. More complex analyses after imputation of missing values are 
unlikely to change this picture.
Pattern of care studies and survival have been conducted separately in Europe5,6 and the 
US24. Here, we could make a direct comparison between Europe and the US with data on 
stage at diagnosis and treatment collected and coded with the same rules.
Overall, women received breast-conserving surgery and radiotherapy for early node-
negative breast cancer somewhat more often in Europe (55%) than the US (49%), but the 
distribution by age was similar. The lower proportion in the US is mainly determined by 
Louisiana (37%) and South Carolina (34%) and may be explained by the attitude of some 
US clinicians during the late 1990s, when radiotherapy may have been considered 
unnecessary after breast-conserving surgery10. Another explanation may be the paucity of 
radiotherapy centres and/or the distance of the nearest radiotherapy facility25 in these two 
states.
After adjusting for age and tumour size within the category of early node-negative disease, 
the odds of being treated with breast-conserving surgery and radiotherapy were almost 60% 
higher in Western Europe than Southern Europe (reference), 20–40% lower in the US and 
Northern Europe, and more than 80% lower in Eastern Europe.
In Denmark, the low level of breast-conserving surgery and radiotherapy was probably 
related to the fact that most breast cancers were treated in local or regional hospitals (not 
specialist centres), rather than any lack of radiotherapy facilities, although the Danish 
national cancer plan of 2000 recognised the need to modernize and expand radiotherapy 
services. Most women receiving breast-conserving surgery also received radiotherapy, but 
breast-conserving surgery was hardly ever done in areas where breast cancer screening was 
not performed26.
About 90% of women aged less than 50 years with node-positive disease received 
chemotherapy in both Europe and the US, in accordance with contemporary clinical 
protocols27.
The proportion of women aged 50–99 years with positive lymph nodes who received 
chemotherapy was notably higher in the US (60% vs. 46%). The proportion was similar in 
all 7 states, but slightly lower in Illinois and Rhode Island. The finding of more active 
treatment for older women in the US echoes the finding for women diagnosed in 1990, and 
may indicate the importance of health insurance programs such as MEDICARE. The US 
National Institutes of Health had also recommended chemotherapy for node-positive breast 
cancer in 198528.
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In the late 1990s, tamoxifen was recommended for estrogen-receptor positive tumours on 
both sides of the Atlantic29,30, especially for women aged over 50 years. In the US, the 
proportion of women aged less than 50 years with ER+ tumours treated with hormonal 
therapy was 58%, higher than in Europe (44%).
The low proportion of women with early stage disease who receive breast-conserving 
surgery is correlated with total national expenditure on health6. The wider use of 
chemotherapy and hormonal treatment may reflect the fact that costs are lower than for 
surgery and radiotherapy. Taken with the findings of this study, this suggests that low 
healthcare expenditure in Eastern European countries may have had an important effect on 
the quality of breast cancer treatment, and on survival.
Differences in breast cancer survival between Europe and the US in the late 1990s were 
mainly explained by lower survival in Eastern Europe, where low healthcare expenditure 
may have constrained the quality of breast cancer treatment. Similarly wide variation has 
also been reported within the US, where non-Hispanic Black women were less likely to 
receive guideline-concordant treatment than non-Hispanic White women8.
The need for population-based data on stage and treatment is recognised by clinicians and 
epidemiologists. High-resolution studies still seem to be the only valid way to collect this 
information. More funding should be directed to help cancer registries obtain timely high-
resolution data for all registered patients.
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Figure 1. 
Five-year age-standardised net survival (%), women diagnosed with primary invasive breast 
cancer in Europe and the US in the late 1990s: country and region
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Table 4
Odds ratio (OR) for women with early node-negative disease (T1N1M0) being treated with breast-conserving 
surgery and radiotherapy (vs. any other surgical procedure, with or without radiotherapy) in each jurisdiction, 
adjusted for age and tumour size
No.1 OR 95% CI
Jurisdiction
 Northern Europe 681 0.60 0.50 0.72
 Western Europe 1,595 1.57 1.36 1.81
 Southern Europe 1,848 1
 Eastern Europe 477 0.16 0.12 0.20
 US 1,185 0.80 0.69 0.94
Age (years)
 15–39 244 1.33 0.99 1.78
 40–49 1,039 1.44 1.21 1.70
 50–59 1,558 1.38 1.19 1.60
 60–69 1,614 1
 70–99 1,331 0.48 0.41 0.56
Tumour size
 Less than 5mm (T1a) 380 0.94 0.75 1.17
 5–10mm (T1b) 1,650 1.31 1.16 1.48
 >10mm, up to 20mm (T1c) 3,756 1
1Number of women with early node-negative disease who were operated, with information on tumour size available
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